How is phesgo administered
Web25 mrt. 2024 · For men: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agree to refrain from donating sperm, during the treatment period and for 7 months after the final dose of Phesgo to avoid exposing the embryo Maintenance Phase Inclusion Criteria Complete a minimum of four … Web10 jul. 2024 · Phesgo has been approved as a treatment for early and metastatic HER2-positive breast cancer. It's administered in the form of an injection that can be given …
How is phesgo administered
Did you know?
WebPhesgo’s RMP. I. THE MEDICINE AND WHAT IT IS USED FOR Phesgo is authorized for metastatic and early breast cancers (see SmPC for the full indication). It contains pertuzumab and trastuzumab as the active substance, and it is given by subcutaneous injection. Further information about the evaluation of Phesgo’s benefits can be found in … WebThere is a pregnancy pharmacovigilance program for PHESGO. If PHESGO is administered during pregnancy, or if a patient becomes pregnant while receiving PHESGO or within 7 months following the last dose of PHESGO, health care providers and patients should immediately report PHESGO exposure to Genentech at 1-888-835-2555.
Web27 jul. 2024 · Anaphylaxis is a severe allergic reaction that can cause hives, low blood pressure, dizziness, chills, and trouble breathing. The healthcare provider who gives you the Phesgo injection will closely monitor you for 30 minutes after your first dose. For later doses, you will be monitored for 15 minutes. WebPhesgo is a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer.
WebWhen administered with PHESGO, the recommended initial dose of docetaxel is 75 mg/m 2 administered as an intravenous infusion. The dose may be escalated to 100 mg/m 2 … WebHow is Phesgo used? Phesgo can only be obtained with a prescription and treatment should be started under the supervision of a doctor who is experienced in using cancer …
Web10 dec. 2024 · numbness, weakness, or pain in your hands or feet. joint pain. mild skin reaction around the IV infusion site, such as irritation, pain, or swelling. Most of these side effects may go away within ...
Webensure that the drug being prepared and administered is Phesgo. Additionally, the fact that Phesgo should be administered via subcutaneous injection only is stated. Outer and … haveri karnataka 581110Web5 jul. 2024 · The drug, Phesgo, can be used for all stages of HER2-positive breast cancer. Experts say it can be administered at home by a healthcare professional more quickly … haveri to harapanahalliWebPHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Select patients for therapy based on an FDA-approved companion diagnostic test. haveriplats bermudatriangelnWebBefore surgery, pertuzumab is given for three to six cycles alongside trastuzumab and chemotherapy. After surgery, it’s given alongside trastuzumab and chemotherapy for … havilah residencialWeb1 nov. 2024 · Administer Phesgo 1,200 mg, 600 mg, 30,000 units/15 mL subcutaneously over approximately 8 minutes Administer Phesgo 600 mg, 600 mg, 20,000 units/10 mL subcutaneously over approximately 5 minutes The subcutaneous injection site should be alternated between the left and right thigh only. havilah hawkinsWeb16 nov. 2024 · Administer PHESGO 1,200 mg, 600 mg, 30,000 units/15 mL subcutaneously over approximately 8 minutes Administer PHESGO 600 mg, 600 mg, 20,000 units/10 mL subcutaneously over approximately 5 minutes The subcutaneous injection site should be alternated between the left and right thigh only. haverkamp bau halternWebWhen administered with PHESGO, the recommended initial dose of docetaxel is 75 mg/m 2 administered as an intravenous infusion. The dose may be escalated to 100 mg/m 2 administered every 3 weeks if the initial dose is well tolerated. Administer PHESGO until disease progression or unmanageable toxicity, whichever occurs first. have you had dinner yet meaning in punjabi